ACRIVON THERAPEUTICS INC

Insider sales at Acrivon Therapeutics show routine tax‑withholding, not loss of confidence, as execs maintain long positions and the stock remains near $2.39.

Insider buying shows Acrivon’s execs bet big on future milestones, hinting the $1.50 stock could be undervalued for long‑term investors.

Insightful CFO buying of Acrivon Therapeutics signals potential upside amid volatile biotech market – see why insider moves matter for investors.

COO’s 10,000‑share buy of Acrivon Therapeutics signals a confidence shift amid a 67% YTD decline, hinting at a potential rebound with upcoming Phase 1 data.